AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01859026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Treatment as outlined in study arms.
Study NCT01859026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment as outlined in study arms.
Study NCT04977596 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective study without intervention
Study NCT00230594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
Study NCT00230594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
Study NCT04204226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Worker
Description: The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
Study NCT04204226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Behavioral Health Navigation (ABHN)
Description: The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
Study NCT04204226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social work + ABHN
Description: After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
Study NCT04204226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social work + ABHN + CAP
Description: After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
Study NCT03818295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-praliciguat
Description: 10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
Study NCT00695383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside cycle exercise therapy
Description: A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
Study NCT00695383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy program
Description: The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
Study NCT00587431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh (Leuprolide)
Description: Leuprolide LUPRON
Study NCT00587431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh (Leuprolide)
Description: Leuprolide LUPRON
Study NCT00587431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
Study NCT00587431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
Study NCT00587431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70 mg/m2 given on day o1 of each 3 week cycle
Study NCT03424655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive
Description: Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
Study NCT03424655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Force
Description: Flex-R files sizes 15-45 taper .02 were used according to the technique
Study NCT03424655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne
Description: WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
Study NCT03424655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc technique
Description: Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
Study NCT00804024 — intervention group
Intervention type: DEVICE
Intervention: ClearWay™ RX Local Therapeutic Infusion Catheter
Description: The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
Study NCT01034852 — intervention group
Intervention type: PROCEDURE
Intervention: Totally Thoracoscopic Maze
Description: Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
Study NCT00769314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir Lauriad
Description: 50 mg muco-adhesive buccal tablets, single application on the gum
Study NCT00769314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg muco-adhesive buccal tablets, single application on the gum
Study NCT04372719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3N2
Study NCT04702035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
Description: All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
Study NCT04702035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
Description: All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
Study NCT01102452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercially Available Wet Noodle
Description: Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
Study NCT01102452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PPB-R-203-02 Noodle
Description: PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
Study NCT03474328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlcoChange
Description: Smartphone app and breathalyser
Study NCT02674386 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Investigational Medical Product (IMP) administered in parent study
Description: IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
Study NCT01634412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 2.4 mg at pH 3.5
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
Study NCT01634412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 2.4 mg at pH 7.1
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
Study NCT01634412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Tablet
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study NCT01634412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine IV
Description: 1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
Study NCT00754871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150037)
Description: daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
Study NCT00754871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150231)
Description: daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
Study NCT00754871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (SH T00660A)
Description: daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
Study NCT00754871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150746)
Description: daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
Study NCT03224520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommender CTHC
Description: Enhanced Messaging
Study NCT03224520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CTHC
Description: Standard Messaging
Study NCT03224520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Recruitment
Description: Tools to facilitate smokers' recruiting their peers
Study NCT03224520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Online Recruitment
Description: Search Engine and Social Media Advertisements
Study NCT01358084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT01358084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT01358084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Study NCT01358084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Study NCT01908205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Study NCT01908205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01230645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Study NCT01230645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Study NCT02734524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Natural killer cell infusion is an intervention between two arms. Dosage of infused cell >1×10\^9，q28d\*4
Study NCT02734524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 135-175mg/m2,q28d\*4
Study NCT02734524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxol
Description: 135-175mg/m2,q28d\*4
Study NCT02734524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5,q28d\*4
Study NCT02734524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=5,q28d\*4
Study NCT01501968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistimethate sodium 2.5-5mg/kg iv per day
Study NCT01501968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin + Ascorbic acid
Description: Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
Study NCT01402973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
Study NCT05044494 — intervention group
Intervention type: PROCEDURE
Intervention: non-prompt surgery
Study NCT01594034 — intervention group
Intervention type: PROCEDURE
Intervention: expired air
Description: collection of expired air from ventilator
Study NCT02020967 — intervention group
Intervention type: OTHER
Intervention: Non-interventional cross-sectional survey
Description: This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
Study NCT01311427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-form Yang-style Tai chi
Description: This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
Study NCT01311427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group education
Description: Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
Study NCT03259789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets, 20 mg
Description: Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Study NCT03259789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexagliflozin tablets, placebo
Description: Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
Study NCT03259789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin tablets, 20 mg
Description: Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Study NCT02523794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-kinetically Modified Water
Description: Subjects assigned to this arm will receive the EMW
Study NCT02523794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Purified Drinking Water
Study NCT01448148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Description: Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
Study NCT01448148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
Study NCT02121418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02121418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02121418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02343744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary.
Study NCT03906630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Telehealth clinical exam
Description: This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
Study NCT03906630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard clinical exam
Description: This is a standard in-person clinical exam for patients presenting with shoulder pain
Study NCT02503202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot A
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
Study NCT02503202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot B
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
Study NCT02503202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot C
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
Study NCT02503202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 High-dose Lot
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
Study NCT02503202 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V920
Description: Sodium chloride 0.9%, sterile solution for intramuscular injection
Study NCT03691961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair sampling
Description: After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
Study NCT03691961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hair's drug concentrations
Description: The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
Study NCT02586454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block
Study NCT02586454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Study NCT02586454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Study NCT02586454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Study NCT02078011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
Study NCT03581968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump.
Study NCT00454792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Back exercise: At home every day. In groups once a week. Duration 10 weeks.